NAVIDEA BIOPHARMACEUTICALS I (NAVB)

US63937X2027 - Common Stock

0.0779  0 (-2.99%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NAVIDEA BIOPHARMACEUTICALS I

NYSEARCA:NAVB (10/5/2023, 7:04:00 PM)

0.0779

0 (-2.99%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-71.67%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap7.80M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NAVB Daily chart

Company Profile

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. The company is headquartered in Dublin Ohio, Ohio and currently employs 11 full-time employees. The firm is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The company has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Company Info

NAVIDEA BIOPHARMACEUTICALS I

Suite 300, 425 Metro Place North

Dublin Ohio OHIO 43017

P: 16147937500.0

CEO: Jed A. Latkin

Employees: 11

Website: https://www.navidea.com/

NAVB News

News Image14 days ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
News Imagea month ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
News Image6 months ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
News Image8 months ago - Seeking AlphaNavidea settles litigation with Capital Royalty, stock rallies 30% (NAVB)

Navidea Biopharmaceuticals (NAVB) and Capital Royalty Partners have entered into a binding agreement and mutual release to settle their long-running litigation. Read more here.

News Image8 months ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
News Image10 months ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

NAVB Twits

Here you can normally see the latest stock twits on NAVB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example